Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Age-adjusted high-dose chemotherapy plus autologous stem cell transplantation vs conventional R-MP in elderly primary CNS lymphoma
2020-001181-10Phase 3Active
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab, methotrexate, cytarabine, thiotepa, busulfan and 1 more in Diffuse Large B-Cell Primary Central Nervous System Lymphoma (2 arms), sponsored by Universitätsklinikum Freiburg. Primary endpoint: Progression-free survival. Started Jan 2023; status: active.
02
Drugs
rituximabmethotrexatecytarabinethiotepabusulfan
03
Conditions
Diffuse Large B-Cell Primary Central Nervous System Lymphoma
Beyond the preview
Go deeper on 2020-001181-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001181-10.